[go: up one dir, main page]

PE20190504A1 - Moduladores del receptor nmda espiro-lactam y uso de los mismos - Google Patents

Moduladores del receptor nmda espiro-lactam y uso de los mismos

Info

Publication number
PE20190504A1
PE20190504A1 PE2019000297A PE2019000297A PE20190504A1 PE 20190504 A1 PE20190504 A1 PE 20190504A1 PE 2019000297 A PE2019000297 A PE 2019000297A PE 2019000297 A PE2019000297 A PE 2019000297A PE 20190504 A1 PE20190504 A1 PE 20190504A1
Authority
PE
Peru
Prior art keywords
nmda
independently selected
espiro
lactam
same
Prior art date
Application number
PE2019000297A
Other languages
English (en)
Inventor
M Amin Khan
Original Assignee
Aptinyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptinyx Inc filed Critical Aptinyx Inc
Publication of PE20190504A1 publication Critical patent/PE20190504A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se refiere a un compuesto representado por la formula expuesta, o una sal farmaceuticamente aceptable y/o estereoisomero del mismo, caracterizado porque: X es O o NR2; R1 y R2 se seleccionan de forma independiente de H, fenilo, entre otros; p es 1 o 2; R3 se selecciona de H, alquiloC1-C6, entre otros; R5 se selecciona de forma independiente de H, ciano, entre otros; y R7 se selecciona de forma independiente de H, halogeno, entre otros; y a formulaciones o composiciones farmaceuticas que comprenden al compuesto de la presente invencion (puede ser su mezcla racemica) junto a un excipiente farmaceuticamente aceptable (segun la via de administracion). Tambien se refiere a metodos de preparacion y de tratamiento (para esto se pueden emplear tambien terapias de combinacion con uno o mas de otros agentes activos). La presente invencion es util para el tratamiento de afecciones como la depresion y trastornos relacionados mediante la modulacion de la actividad del receptor de N-metil-d-aspartato (NMDA).
PE2019000297A 2016-08-01 2017-08-01 Moduladores del receptor nmda espiro-lactam y uso de los mismos PE20190504A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662369456P 2016-08-01 2016-08-01

Publications (1)

Publication Number Publication Date
PE20190504A1 true PE20190504A1 (es) 2019-04-10

Family

ID=59593191

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000297A PE20190504A1 (es) 2016-08-01 2017-08-01 Moduladores del receptor nmda espiro-lactam y uso de los mismos

Country Status (17)

Country Link
US (3) US10918637B2 (es)
EP (1) EP3490993B1 (es)
JP (1) JP7032378B2 (es)
KR (1) KR102465757B1 (es)
CN (1) CN109890825B (es)
AU (1) AU2017305240B2 (es)
CA (1) CA3031539C (es)
CL (1) CL2019000247A1 (es)
CO (1) CO2019000943A2 (es)
EA (1) EA201990428A1 (es)
ES (1) ES2973283T3 (es)
IL (2) IL286107B2 (es)
MX (1) MX386938B (es)
PE (1) PE20190504A1 (es)
PH (1) PH12019500206A1 (es)
SG (1) SG11201900551WA (es)
WO (1) WO2018026782A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740628C (en) 2008-09-18 2018-05-01 Naurex, Inc. Nmda receptor modulators and uses thereof
LT2951183T (lt) 2013-01-29 2019-05-27 Aptinyx Inc. Spiro-laktamo nmda receptorių moduliatoriai ir jų panaudojimas
KR101518972B1 (ko) 2014-08-01 2015-05-18 제이더블유크레아젠 주식회사 수지상세포의 제조방법, 이에 의해 제조된 수지상세포 및 그 용도
PE20190502A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
AU2017306164B2 (en) 2016-08-01 2021-10-21 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam NMDA modulators and methods of using same
MX385336B (es) 2016-08-01 2025-03-18 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
US11299495B2 (en) 2016-08-01 2022-04-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2018026782A1 (en) * 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP7210599B2 (ja) 2018-01-31 2023-01-23 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
KR20230027097A (ko) 2020-06-03 2023-02-27 앱티닉스 인크. 스피로-락탐 화합물 및 바이러스 감염의 치료 방법

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180398A1 (en) 1984-10-26 1986-05-07 The Regents Of The University Of California Synthesis of beta-lactam
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5350769A (en) 1990-10-30 1994-09-27 Ss Pharmaceutical Co., Ltd. Antiinflammatory gel preparation
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
JP2000512277A (ja) 1996-06-07 2000-09-19 ゼネカ・リミテッド ペプチド誘導体
AU3972797A (en) 1996-08-02 1998-02-25 Zymogenetics Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
AU1585999A (en) 1997-11-12 1999-05-31 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
WO2000028090A2 (en) 1998-11-12 2000-05-18 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
AU1922301A (en) 1999-11-17 2001-05-30 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
EP1255854A2 (en) 2000-02-01 2002-11-13 Agy Therapeutics, Inc. Interaction of nmda receptor with protein tyrosine phosphatase
AU2001268467A1 (en) 2000-06-14 2001-12-24 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
CA2413974A1 (en) 2000-06-22 2001-12-27 Nyxis Neurotherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
US20020142287A1 (en) 2000-12-14 2002-10-03 Hirotaka Yamamoto High throughput assay to detect inhibitors of the map kinase pathway
WO2002072005A2 (en) 2001-03-07 2002-09-19 University Of Utah Research Foundation Linear y-carboxyglutamate rich conotoxins
AU2002255705A1 (en) 2001-03-12 2002-09-24 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
US20030022253A1 (en) 2001-07-25 2003-01-30 Nyxis Neurotherapies, Inc. Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby
PL374434A1 (en) 2002-07-05 2005-10-17 Targacept, Inc. N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2005014797A2 (en) 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
US7662856B2 (en) 2003-08-29 2010-02-16 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
GB0323204D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
RS52471B (en) 2005-03-24 2013-02-28 Emory University DOSAGE MODES FOR TREATMENT OF TRAUMATIC BRAIN INJURY BY PROGESTERON
WO2007013691A1 (ja) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited スピロ環化合物
US7951912B2 (en) 2005-08-26 2011-05-31 Wisconsin Alumni Research Foundation Poly-β-peptides from functionalized β-lactam monomers and antibacterial compositions containing same
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
MX2009002921A (es) 2006-09-15 2009-04-01 Schering Corp Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
JP2008188285A (ja) 2007-02-06 2008-08-21 Bridgestone Corp バックパッド及び車両用シート
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
WO2009105718A1 (en) 2008-02-20 2009-08-27 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism
AU2009264307A1 (en) 2008-06-24 2009-12-30 Intervet International B.V. Pharmaceutical transdermal compositions and method for treating inflammation in cattle
AU2009264334A1 (en) 2008-06-27 2009-12-30 Neurosearch A/S Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
KR101647520B1 (ko) 2008-08-07 2016-08-10 에프. 호프만-라 로슈 아게 거대환식 화합물의 제조 방법
GB0814991D0 (en) 2008-08-15 2008-09-24 Glaxo Group Ltd Compounds
CA2740628C (en) 2008-09-18 2018-05-01 Naurex, Inc. Nmda receptor modulators and uses thereof
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
DE102009001460B4 (de) 2009-03-11 2010-12-02 Zf Friedrichshafen Ag Ölbehälter
WO2011003064A2 (en) 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
EP2985032B1 (en) 2009-10-05 2019-01-02 Northwestern University Glyx for use in the treatment of alzheimer's disease, parkinson's disease or huntington's disease
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
MX2012009388A (es) 2010-02-11 2012-10-01 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato estabilizado de estructura secundaria y sus usos.
US8097634B2 (en) 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
WO2012021712A1 (en) 2010-08-12 2012-02-16 Tetraphase Pharmaceuticals, Inc. Tetracycline analogs
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN108283712A (zh) 2011-04-27 2018-07-17 西北大学 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法
CN103635264B (zh) 2011-06-27 2016-06-01 皇家飞利浦有限公司 超声换能组件及其制造方法
PT3686194T (pt) 2011-07-27 2021-11-11 Astrazeneca Ab Compostos de 2-(2,4,5-anilino-substituídos)pirimidina
LT2951183T (lt) 2013-01-29 2019-05-27 Aptinyx Inc. Spiro-laktamo nmda receptorių moduliatoriai ir jų panaudojimas
EA032153B1 (ru) 2013-01-29 2019-04-30 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
JP6419087B2 (ja) 2013-01-29 2018-11-07 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
CN105026401A (zh) 2013-01-29 2015-11-04 诺雷克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
JP2016506962A (ja) * 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
MX378566B (es) 2016-05-19 2025-03-11 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2017306164B2 (en) 2016-08-01 2021-10-21 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam NMDA modulators and methods of using same
WO2018026782A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190502A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
MX385336B (es) 2016-08-01 2025-03-18 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
US11299495B2 (en) 2016-08-01 2022-04-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CA3089559A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP7210599B2 (ja) 2018-01-31 2023-01-23 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Also Published As

Publication number Publication date
CN109890825B (zh) 2022-03-11
WO2018026782A1 (en) 2018-02-08
MX386938B (es) 2025-03-19
IL286107A (en) 2021-10-31
JP2019527234A (ja) 2019-09-26
JP7032378B2 (ja) 2022-03-08
MX2019001321A (es) 2019-07-04
ES2973283T3 (es) 2024-06-19
EP3490993B1 (en) 2023-12-06
SG11201900551WA (en) 2019-02-27
US20190175588A1 (en) 2019-06-13
KR102465757B1 (ko) 2022-11-09
IL286107B1 (en) 2024-05-01
AU2017305240B2 (en) 2021-12-09
KR20190033594A (ko) 2019-03-29
US10918637B2 (en) 2021-02-16
PH12019500206A1 (en) 2019-06-17
US20230131402A1 (en) 2023-04-27
EA201990428A1 (ru) 2019-08-30
IL264495B (en) 2021-09-30
CA3031539A1 (en) 2018-02-08
US11376250B2 (en) 2022-07-05
IL286107B2 (en) 2024-09-01
CL2019000247A1 (es) 2019-06-21
US20210322406A1 (en) 2021-10-21
EP3490993A1 (en) 2019-06-05
CA3031539C (en) 2023-11-28
EP3490993C0 (en) 2023-12-06
CN109890825A (zh) 2019-06-14
CO2019000943A2 (es) 2019-02-08
AU2017305240A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
PE20190504A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20190501A1 (es) Moduladores nmda espiro-lactam y metodos de uso de los mismos
PE20190503A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20190500A1 (es) Moduladores del receptor nmda spiro-lactam y uso de los mismos
PE20190502A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
PE20180232A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
MX2017007489A (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos.
JOP20210005A1 (ar) عوامل تحلل مستقبلات الإستروجين الانتقائية
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
EA201171488A1 (ru) Lxr модуляторы
MX393586B (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
PE20240930A1 (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
AR094550A1 (es) Inhibidores de btk
AR092288A1 (es) Ligandos del receptor ep1
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
AR094735A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4
MX394108B (es) Derivados de indol n-sustituidos.
PE20181328A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
AR089122A1 (es) Formulaciones orales para tratar la sobrecarga de metales
PE20141527A1 (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, preparacion de los mismos y su uso terapeutico de los mismos